The system at Tongji Hospital will feature Mevion’s industry leading HYPERSCAN® Pencil Beam Scanning (PBS) technology, coupled with the industry’s only proton multi-leaf collimator, the Adaptive Aperture®. This powerful duo provides faster and more precise targeted dose delivery to tumors thus further minimizing the damage to surrounding healthy tissue and organs at risk. The system also integrates a diagnostic CT imaging system and a surface tracking system for high precision patient positioning and intra-fraction motion management.

Founded in 1900 and listed as the 6^th top hospital in Fudan’s 2020 China Hospital Ranking, Tongji Hospital provides over 6 million annual outpatient visits. The contract for the new proton therapy center was completed in late 2021, and construction of the new 135,000 square-foot proton therapy center at Tongji Hospital’s Optics Valley campus is expected to be completed by December 2022. The installation of the MEVION S250i is planned to commence in July.

Tongji Hospital will build a second proton vault simultaneously, making it China’s first proton center applying the One Plus One multi-system installation approach. This allows Tongji Hospital the flexibility to add a second system in the future to correspond to the growth of patient volume and clinical expertise. This staged installation significantly reduces the financial burden at the start of the clinical proton therapy program and minimizes the risk of technology obsolescence.

“Mevion is proud to partner with the distinguished Tongji Hospital to provide accessible proton therapy to their patients,” said Tina Yu, Ph.D., chief executive officer and president of Mevion. “Mevion strongly believes health care systems will greatly benefit from expanding their proton centers at their optimal pace with the most advanced technology to best serve their patients.”